Immunovia’s pipeline is composed of two types of projects:
- Early phase research projects in collaboration with academic centers based on the IMMray™ platform and other patents held by Immunovia, see section Other cancers and Autoimmune diseases
- Ongoing development of diagnostic tests based on the IMMray™ platform in pancreatic cancer and rheumatoid arthritis diagnostics, are described in Clinical applications
Discovery projects may often generate patents, also in early stages, and as Immunovia has an extensive patent strategy, results generated at academic collaborations such as CREATE Health translational cancer center at Lund University, are patented when there is a potential future commercial opportunity. These early patents are followed through with additional patents for the indications as further studies are completed for the application where either additional research projects are performed or the project is moved to Immunovia for development studies.
Research projects may often generate results that lead to further studies before final conclusions can be made regarding the maturity to transfer to Immunovia for development. Hence it is not possible to predict the timing of such transfer and we will report on progress of projects from the time of transfer to Immunovia.
Early patent portfolios based on research studies in academia include Prostate Cancer, Breast Cancer and Autoimmune diseases of which the Autoimmune research program has reached maturity and been transferred to Immunovia.